The LDN Book 3: Low Dose Naltrexone

The LDN Book 3 (Low Dose Naltrexone) Is an invaluable science-based resource for patients and clinicians. Treating patients suffering from chronic inflammatory conditions such as Long COVID, Mold, CIRS, latent viral infections, cancer, refractive depression etc. Drugs typically are something you want to avoid, but LDN can be a game changer.

“The LDN Book 3 gives valuable insight into the drug of the decade. The immense knowledge within can change and improve the quality of life. For many, it’s a game changer.” -- Nat Jones, R.Ph. FAPC, Clinical Compounding Pharmacist

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers. It has been used to help those with autism, chronic fatigue, and depression find relief, and latest research points to its potential for long covid, mold toxicity, even longevity. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity? Find out more about the potential of LDN from leading international medical professionals in this updated, third book, edited by Linda Elsegood, founder of The LDN Trust.

• | Author: Linda Elsegood
• | Publisher: LDN Research Trust
• | Publication Date: Nov 10, 2022
• | Number of Pages:
• | Language:
• | Binding: Paperback / softback
• | ISBN-13: 9781739107000
• | ISBN-10: 1739107004